Table 1 Current research status of oncolytic viruses
From: Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
Virus | Types of cancer | Research institution | Experimental phase | NCT number |
|---|---|---|---|---|
HSV | Melanoma | Bristol-Myers Squibb/Takara Bio Inc | Phase II | NCT01017185 |
Solid tumor | Wuhan Binhui Biotechnology Co. Ltd | Phase I | NCT04386967 | |
Gastrointestinal cancer | Wuhan Binhui Biotechnology Co. Ltd | Phase II | NCT05648006 | |
Pancreatic cancer | Wuhan Binhui Biotechnology Co. Ltd | Phase I/II | NCT04637698 | |
High-grade glioma | University of Alabama at Birmingham | Phase II | NCT05632562 | |
Solid tumor | Takara Bio Inc | Phase I | NCT01017185 | |
NDV | Metastatic cancer | Hadassah Medical Organization | Phase II | NCT00348842 |
Ad | Recurrent glioblastoma | National Cancer Institute (NCI) | Phase I | NCT00004080 |
Pancreatic cancer | Lokon Pharma AB | Phase I/II | NCT02705196 | |
Primary peritoneal cancer | University of Alabama at Birmingham | Phase I | NCT00562003 | |
Solid tumor | TILT Biotherapeutics Ltd | Phase I | NCT04695327 | |
Liver cancer | Emergent BioSolutions | Phase I | NCT03160339 | |
Recurrent glioblastomaLung | Clinica Universidad de Navarra | Phase I | NCT03714334 | |
Cancer (NSCLC) | Benjamin Movsas, M.D | Phase I | NCT03029871 | |
Ovarian cancer | TILT Biotherapeutics Ltd | Phase I | NCT05271318 | |
Advanced/metastatic solid tumours | Canadian Cancer Trials Group | Phase I | NCT02285816 | |
VSV | Endometrial cancer | Mayo Clinic | Phase I | NCT03120624 |
Advanced malignant solid neoplasm | Mayo Clinic | Phase I | NCT01628640 | |
Hepatocellular carcinoma | Mayo Clinic | Phase I | NCT01628640 | |
Reovirus | Recurrent melanoma | National Cancer Institute (NCI) | Phase I | NCT00651157 |
Unspecified childhood solid tumor | National Cancer Institute (NCI) | Phase II | NCT01240538 | |
Recurrent primary peritoneal carcinoma | National Cancer Institute (NCI) | Phase II | NCT00602277 | |
Pancreatic acinar cell carcinoma | National Cancer Institute (NCI) | Phase II | NCT01280058 | |
Metastatic melanoma | National Cancer Institute (NCI) | Phase II | NCT00651157 | |
Metastatic colorectal cancer | Oncolytics Biotech | Phase I | NCT01274624 | |
MV | Malignant pleural mesothelioma | Mayo Clinic | Phase I | NCT01503177 |
Anaplastic astrocytoma | Mayo Clinic/National Cancer Institute (NCI) | Phase I | NCT00390299 | |
Glioblastoma | Mayo Clinic/National Cancer Institute (NCI) | Phase I | NCT02709226 | |
Stage IV breast cancer | Mayo Clinic/National Cancer Institute (NCI) | Phase I | NCT04521764 | |
Recurrent non-small cell Lung cancer | Vyriad, Inc | Phase I | NCT00002625 | |
Malignant mesothelioma | University of Arkansas | Phase I | NCT01503177 | |
Metastatic breast cancer | Mayo Clinic | Phase I | NCT01846091 | |
Poxvirus | Advanced tumors | Hangzhou Converd Co., Ltd | Phase I | NCT05914376 |
Refractory cancer | National Cancer Institute (NCI) | Phase I/II | NCT02759588 | |
Malignant solid tumors | Tasly Tianjin Biopharmaceutical Co., Ltd | Phase I/II | NCT04226066 | |
Hepatic carcinoma | Jennerex Biotherapeutics | Phase II | NCT00554372 | |
Hepatic carcinoma | Jennerex Biotherapeutics | Phase I | NCT00629759 | |
Advanced solid tumors | Genelux Corporation | Phase I | NCT00794131 | |
Renal cell carcinoma | SillaJen, Inc | Phase I/II | NCT03294083 |